No business profile yet.
Size Ever Supreme Bio Technology (6712.TWO) is a Taiwan Health Care company (Biotechnology) with a market value of $427M, the 480th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$142.00 on 18 Nov 2026.
Performance Over six months the shares gained 10.9%, against -22.5% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 13.3% over the last twelve months (peer median +1.7%); the operating margin is 46.9% (peer median -17.2%).
Valuation It trades at 26.2× forward earnings against a peer median of 33.9× (3rd cheapest of 6).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +71%, so the hurdle is -65 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 9.7 points above its cost of capital (5.0% WACC).
Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$1.14B | NT$1.02B | NT$889M | NT$758M | NT$628M |
| Revenue growth | — | +14% | +17% | +21% | — |
| Gross profit | NT$892M | NT$711M | NT$597M | NT$466M | NT$396M |
| EBITDA | n/a | NT$462M | NT$452M | NT$370M | NT$319M |
| Net income | NT$464M | NT$429M | NT$367M | NT$539M | NT$201M |
| Free cash flow | n/a | NT$535M | NT$435M | NT$416M | NT$316M |
| Capital expenditure | n/a | NT$48.8M | NT$46.2M | NT$5.83M | NT$8.11M |
| Total debt | n/a | NT$38.7M | NT$2.84M | NT$5.90M | NT$17.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6712.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.6% | -13.4% | 9th highest of 21 |
| 6-month return | +10.9% | -22.5% | 3rd highest of 21 |
| Distance from 52-week high | -22.8% | -46.2% | highest of 21 |
| Revenue growth (TTM) | +13.3% | +1.7% | 8th highest of 17 |
| Operating margin | 46.9% | -17.2% | 3rd highest of 17 |
| Forward P/E | 26.2× | 33.9× | 3rd cheapest of 6 |
| Growth the price implies (Req g, 7 yrs) | 5.3% | -6.6% | 2nd most demanding of 7 |
| Growth delivered (Del g) | +70.5% | +0.5% | 2nd highest of 6 |
| Hurdle (Req g minus delivered) | -65.2 pp | +1.6 pp | 2nd least demanding of 6 |
| ROIC minus cost of capital | +9.7 pp | -12.7 pp | 2nd highest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $427M | +11% | +13% | 47% | 26.2× | 5.3% | +70.5% |
| Qyuns Therapeutics 2509.HK | Hong Kong | $428M | -11% | +230% | 56% | 10.2× | -19.5% | n/a |
| Prothena PRTA | United States | $429M | -11% | +347% | -73% | n/a | n/a | n/a |
| Medigen Vaccine Biologics 6547.TWO | Taiwan | $424M | -8% | +44% | -5% | 170.0× | n/a | n/a |
| Shanghai ZJ Bio-Tech 688317.SS | China | $422M | -22% | -10% | -72% | n/a | 4.0% | -62.3% |
| Scinopharm Taiwan 1789.TW | Taiwan | $435M | -2% | -5% | -4% | 39.4× | 2.1% | +0.5% |
| Rznomics 476830.KS | South Korea | $418M | -76% | -65% | -1,112% | n/a | n/a | n/a |
| Candel Therapeutics CADL | United States | $417M | -31% | n/a | n/a | n/a | n/a | n/a |
| Qingdao Vland Biotech 603739.SS | China | $437M | -24% | +5% | 7% | 33.9× | 7.7% | +7.3% |
| G2GBIO 456160.KS | South Korea | $416M | -53% | -45% | -2,884% | n/a | n/a | n/a |
| Shanghai Serum Bio-Technology 688163.SS | China | $416M | -34% | -1% | 26% | n/a | n/a | n/a |
| Berry Genomics 000710.SZ | China | $439M | -17% | -2% | -24% | n/a | n/a | n/a |
| Eupraxia Pharmaceuticals EPRX.TO | Canada | $416M | +1% | n/a | n/a | n/a | n/a | n/a |
| IRulya Therapeutics IRLA | United States | $440M | +88% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Obio Technology (Group) 688238.SS | China | $414M | -5% | +20% | -79% | n/a | n/a | n/a |
| Arvinas ARVN | United States | $443M | -26% | -12% | -10% | n/a | n/a | n/a |
| EirGenix 6589.TW | Taiwan | $444M | +15% | +58% | -51% | n/a | n/a | n/a |
| Edding Genor 6998.HK | Hong Kong | $410M | -35% | +1,418% | 26% | n/a | -15.3% | +197.3% |
| Hanx Biopharmaceuticals (Wuhan) 3378.HK | Hong Kong | $409M | -24% | n/a | n/a | n/a | n/a | n/a |
| Jacobio Pharmaceuticals 1167.HK | Hong Kong | $404M | -24% | +286% | 68% | 5.7× | -18.8% | -36.1% |
| Qurient 115180.KS | South Korea | $452M | -56% | -14% | -512% | n/a | n/a | n/a |